Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on two highly anticipated trials for head and neck squamous cell carcinoma/HNSCC. The announcements for these presentations were made earlier in May.

Merus presented data from its Phase II study of petosemtamab, which is a bispecific monoclonal antibody targeting epidermal growth factor receptor/EGFR and Leucine-rich repeat containing G-Protein coupled receptor 5/LGR5, in combination with Merck’s Keytruda (pembrolizumab) for PDL1+ first-line (1L) HNSCC.

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

A scientist looking through a microscope conducting research in an immuno-oncology lab.

Bicara presented Phase I/Ib data for its ficerafusp alfa, a bispecific fusion protein targeting EGFR and transforming growth factor beta (TGF-β), also in combination with Keytruda in the same patient population. Both Merus and Bicara are progressing their assets into Phase III clinical development. However, Bicara’s ficerafusp alfa is being advanced with a narrower patient population, specifically excluding those positive for human papillomavirus/HPV.

Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that develops antibody therapeutics in the Netherlands.

While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.